Aerie's Rhopressa wins FDA panel votes

An FDA advisory committee voted 9-1 on Friday that the efficacy of Rhopressa netarsudil 0.02% from Aerie Pharmaceuticals Inc. (NASDAQ:AERI) shown in clinical

Read the full 238 word article

How to gain access

Continue reading with a
two-week free trial.